Clinical trials: WHIM
Marginal Zone Lymphoma
[68Ga]Ga-PentixaFor-PET Imaging for Staging of Marginal Zone Lymphoma
This will be a pivotal prospective prospective, international, multi-center, comparative, randomized, cross-over, open-label lymphoma diagnostic trial to assess the diagnostic performance and safety of the positron emission…
- Trial name
- LYMFOR (NCT06125028)
- Testing
- [68Ga]Ga-PentixaFor, [18F]Fluorodeoxyglucose
- Where
- 12 sites in Austria, France and 3 more
- Volunteers
- 8 people
- Sponsor
- Pentixapharm AG
Waldenstrom's Macroglobulinemia
A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
The primary objective of the study is to establish a pharmacologically active dose of mavorixafor in combination with ibrutinib based on pooled safety, clinical response, pharmacokinetic (PK) and pharmacodynamic (PD) data to…
- Trial name
- NCT04274738
- Testing
- Mavorixafor, Ibrutinib
- Where
- 5 sites in United States, Greece
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
Non-Hodgkin Lymphoma, Multiple Myeloma
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
The purpose of this study is to determine the uptake of the imaging agent [68Ga]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and…
- Conditions
- Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease
- Trial name
- NCT05093335
- Testing
- [68Ga]-Pentixafor
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Leukemia
Study Assessing RLT Using [177Lu]Lu-PentixaTher for Relapsed/Refractory CXCR4+ Acute Leukemia.
CXCR4 inhibition may represent a new therapeutic strategy in acute leukemia (AL) patients, not only by increasing chemosensitivity but also by preventing relapse of the disease by disruption of the interaction of residual…
- Trial name
- PENTILULA (NCT06356922)
- Testing
- Experimental drug [177Lu]Lu-PentixaTher
- Where
- 4 sites in France
- Volunteers
- 21 people
- Sponsor
- Nantes University Hospital
Laryngeal Cancer, Hypopharyngeal Cancer
The Role of MMPs in the CXCL12-Induced Invasion of Laryngeal and Hypopharyngeal Squamous Cell Carcinoma
Investigate the role of MMPs in the CXCL12-induced invasion of laryngeal and hypopharyngeal squamous cell carcinoma
- Trial name
- NCT00302562
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
WHIM Syndrome
A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome
This natural history study is a prospective and retrospective, observational study of WHIM patients. WHIM syndrome is a rare, genetic, primary immunodeficiency disorder (a disorder in which the body's immune system does not…
- Trial name
- NCT03087370
- Testing
- No intervention
- Sponsor
- X4 Pharmaceuticals
Neutropenia
AMD 3100 for Treatment of Myelokathexis
This is an initial study to determine if CXCR4 inhibitor AMD 3100 or plerixafor may be a potential treatment for neutropenia due to CXCR4 mutations, the myelokathexis or WHIM (warts, hypogammaglobulinemia, immunodeficiency and…
- Trial name
- NCT01058993
- Testing
- AMD3100 or plerixafor
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work in treating patients with pancreatic cancer that has spread to other places.
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02907099
- Testing
- CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Aldosteronism With Bilateral Adrenal Lesions
68Ga-Pentixafor PET/CT for Guiding Surgical Treatment of Primary Aldosteronism With Bilateral Adrenal Lesions
Screening potential candidates who may benefit from surgery remains challenging for patients diagnosed with primary aldosteronism (PA) accompanied by bilateral adrenal lesions.
- Trial name
- NCT06247566
- Where
- China
- Volunteers
- 83 people
- Sponsor
- Central South University
Advanced Solid Tumor, Multiple Myeloma
Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.
Phase 1, monocentric, open labeled, no profit "Microdose" trial. A single microdose of the new [68Ga]Ga-R54 PET radiopharmaceutical directed against CXCR4 will be injected into patients with advanced solid tumor or multiple…
- Trial name
- NCT07577206
- Testing
- [68Ga]Ga-R54 PET/CT
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute, Naples
WHIM Syndrome
A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
This is a Phase 2 study with an initial 24-week Treatment Period and an Extension Phase. The primary objectives of this Phase 2 study are to determine the safety, tolerability, and dose selection of mavorixafor in participants…
- Trial name
- NCT03005327
- Testing
- X4P-001
- Where
- 2 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- X4 Pharmaceuticals
Autism Spectrum Disorder, Complication of Prematurity
Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months
Preterm children are at increased risk for autism spectrum disorders, with an estimated rate of 10%. In the US, about 1 in 8 pregnancies ends with a premature birth.
- Trial name
- ASD-CXCR4 (NCT01686685)
- Where
- Israel
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Hadassah Medical Organization
Healthy
Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers
Phase I study to determine and compare the safety/tolerability of single ascending doses of POL6326 by intravenous infusion.
- Trial name
- NCT01841476
- Testing
- POL6326
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Polyphor Ltd.
Myocardial Infarction, Myocardial Injury
Lymphatic Organs and Myocardium After Myocardial Infarction
The adaptive immune response plays an important role in myocardial healing and remodeling after acute myocardial infarction in patients. Therefore, the involved lymphocytes represent a novel target for therapeutic interventions.
- Conditions
- Myocardial Infarction, Myocardial Injury, Myocardial Inflammation
- Trial name
- LOMI (NCT05519735)
- Testing
- Multimodality Imaging
- Where
- 2 sites in Germany
- Volunteers
- 57 people
- Sponsor
- Wuerzburg University Hospital
HIV Infections, Human Immunodeficiency Virus
SP01A: The Study of an Oral Entry Inhibitor in Treatment-Experienced HIV Patients
This is a 28-day, multi-center, placebo-controlled study designed to look at the dose response, efficacy, and safety of SP01A, given as a pill to be swallowed, in the treatment of HIV-infected subjects.
- Trial name
- NCT00299897
- Testing
- SP01A
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Samaritan Pharmaceuticals, Inc
Leukemia, Myeloid, Acute
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia
This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML.
- Trial name
- AMD3100+MEC (NCT00512252)
- Testing
- AMD3100, Mitoxantrone, Etoposide
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Systemic Lupus Erythematosus (SLE)
Auto-immunity in Lupus Patients After Influenza Vaccine
Annual influenza vaccination is recommended in patients with systemic lupus erythematosus (SLE). However some concerns remain about vaccination and the risk of lupus flare
- Trial name
- GRIPLUP (NCT01072734)
- Testing
- Vaccine
- Where
- France
- Volunteers
- 28 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
WHIM, Warts
Base-Edited Hematopoietic Stem/Progenitor Cell Gene Therapy for Treatment of CXCR4-WHIM
Background: Warts, hypogammaglobulinemia, infections and myelokathexis syndrome (WHIMs) is a rare disorder that affects the immune system. People with WHIMs can have severe infections all over their body.
- Conditions
- WHIM, Warts, Hypogammaglobulinemia, Immunodeficiency
- Trial name
- NCT07775313
- Testing
- Busulfan, Palifermin, Plerixafor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Small Cell Lung Carcinoma (SCLC)
Evaluation of the Value of [68Ga]Ga-PENTIXAFOR PET-CT in Patients With Metastatic Small Cell Lung Cancer (SCLC)
[68Ga]Ga-PentixaFor PET-CT will be performed in patients with Small cell lung cancer (SCLC) to confirm the targeting of CXCR4 by [68Ga]Ga-PentixaFor
- Trial name
- PASSIFLORE (NCT07007325)
- Testing
- [68Ga]Ga-PentixaFor
- Where
- 3 sites in France
- Volunteers
- 15 people
- Sponsor
- Institut Cancerologie de l'Ouest
Oral Cancer
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma
Investigate the role of SDF-1/CXCR4 in the metastasis of oral squamous cell carcinoma
- Trial name
- NCT00173849
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital